Barinthus Biotherapeutics Plc. EBIT

Barinthus Biotherapeutics Plc. (BRNS) currently reports a EBIT of $-17M as of June 2026. That compares with $-40M in the prior-year period — up 58.6% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Barinthus Biotherapeutics Plc.'s EBIT history and peer comparisons.

Barinthus Biotherapeutics Plc.'s EBIT increased from $-40M to $-17M — a 58.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Barinthus Biotherapeutics Plc.'s EBIT of $-17M is lower than the Healthcare sector average of $22B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Barinthus Biotherapeutics Plc. reported $-17M in EBIT as of June 2026. That compares with $-40M in the prior-year period — up 58.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-17M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Barinthus Biotherapeutics Plc., and consider following BRNS for alerts when major investors trade the stock.